beigene.com (ONC) - Company Total Revenue

Corporate emblem and logo of BeiGene (ONC)

The revenue chart for BeiGene Ltd (ONC) demonstrates asset dynamics, where 6.63 indicates the level of this metric. As part of its ESG strategy, BeiGene Ltd is implementing energy saving and safe waste disposal in its laboratories. The commercialization of key oncology drugs ensures a predictable cash flow and high margins. The global promotion of Brukinsa and the launch of targeted therapies are creating a powerful growth impulse for current revenues.

BeiGene Corp (ONC) Revenue and Sales Volume: for the period 07/04/2022 - 11/15/2026
Original product of BeiGene Oncology

To objectively assess the operational success of BeiGene Ltd (ONC), it is necessary to analyze actual cash flow. This indicator aggregates daily inflows, and the company's current sales dynamics clearly demonstrate the intensity of demand. Stable growth confirms the absence of systemic business degradation. For the issuer, this reflects the global expansion of innovative oncology drugs. The positive trend indicates a successful capture of global blood cancer therapy markets.

Competing companies

Company Total Revenue Halozyme Therapeutics HALO|Company Revenue Revolution Medicines, Inc. (RVMD)|Revenue and Sales Volume Ascentage Pharma Group International (AAPG)|Revenue and Sales Volume CGON (CG Oncology Inc)|Company Sales Revenue URGN|bicara.com - Revenue and Sales Volume|Company Sales Revenue PSNL (personalis.com)|Erasca Inc (ERAS) - Company Revenue|Company Sales Delcath Systems|YMAB (YmAbs) - Revenue and Sales Volume|AURA: Company Sales Revenue|Company Revenue Candel Therapeutics, Inc. (CADL)|Revenue and Sales Volume Accuray (ARAY)|Company Revenue SELLAS Life Sciences Group Inc. SLS|Actuate Therapeutics, Inc (ACTU) - Company Total Revenue|CTOR - Company Revenue|HURA: Company Revenue|TARA (Protara) - Company Sales|Fate Therapeutics, Inc. - Company Sales Revenue|WHWK (aadibio.com) - Revenue and Sales Volume|TCRX: Company Sales Revenue|Company Revenue Champions Oncology (CSBR)|XBiotech - Company Sales Volume|Company Revenue CEL-SCI CVM|Company Gross Revenue OS Therapies (OSTX)|Radiopharm Theranostics Limited - Revenue and Sales Volume|Company Total Revenue Artiva Biotherapeutics|ANL (adlainortye.com) - Company Sales|Company Sales Veru Pharma|TPST (Tempest Therapeutics Inc) - Revenue and Sales Volume|Xilio Therapeutics, Inc. (XLO) - Company Gross Revenue|Company Revenue Enochian BioSciences (RENB)|MURA: Company Annual Revenue|Revenue and Sales Volume KAPA (kairospharma.com)|Company Gross Revenue OnKure (OKUR)|CytoMed Therapeutics Ltd - Revenue and Sales Volume|curis.com (CRIS) - Company Sales|Apollomics Corp (APLM) - Company Revenue|Tharimmune - Company Sales Revenue|ADVB (Advanced Biomed Corp) - Revenue and Sales Volume|Company Sales Genprex, Inc (GNPX)|Revenue and Sales Volume CLDI|SBFM: Company Annual Revenue|Revenue and Sales Volume XBIO (xeneticbio.com)|Revenue and Sales Volume Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Revenue and Sales Volume|Company Total Revenue American Oncology Network, Inc.|BGNE: Revenue and Sales Volume|Company Sales checkpointtx.com|Company Revenue Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Company Gross Revenue|Company Revenue Ikena (IKNA)|NTBL - Company Total Revenue|Company Revenue viracta.com VIRX|morphosys.com (MOR) - Company Total Revenue|NAYA Biosciences Inc - Revenue and Sales Volume|AAPGV: Company Revenue